PMH59 Use of Attention-Deficit/Hyperactivity Disorder (ADHD) Drugs in Canada, 2010-2014  by Aziz, S. et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A125
representative community-dwelling Medicare beneficiaries < 65 were included 
(n= 10,384 person-years, weighted n= 30,086,849 person-years). Psychotropic pre-
scription utilization included self-reported antidepressants, antipsychotics, stim-
ulants, mood stabilizers, anxiolytics, hypnotics, and antimanic prescription use. 
Weighted annual trends in psychotropic prescription utilization were estimated. 
Repeated person-year data using generalized estimating equations multivariable 
models were used to identify factors associated with psychotropic prescription 
utilization. RESULTS: Annual prevalence of any psychotropic prescription utiliza-
tion among disabled Medicare beneficiaries < 65 increased from 53.4% to 57.9% in 
2002-2009, but the trend was not statistically significant (P= 0.36). Antidepressants 
(35.09%), hypnotics (20.16%), and anxiolytics (17.31%) were the top three therapeutic 
classes used in 2009. No significant trend in utilization was observed for any indi-
vidual therapeutic classes. Multivariable results showed that beneficiaries < 65 who 
were female, white, divorced, Medicare-Medicaid dual eligible, with higher educa-
tion and poorer health status, smoking, and having chronic and psychiatric condi-
tions were more likely to use any psychotropic prescriptions (all P< 0.05). Female 
and white beneficiaries were more likely to use all psychotropic therapeutic classes 
except for antipsychotics (females only) and stimulants/antimanics (whites only). 
Beneficiaries with poorer health status and chronic conditions were more likely to 
use antidepressants, anxiolytics, and hypnotics. Medicare-Medicaid dual enrollees 
were more likely to use antipsychotics (all P< 0.05). CONCLUSIONS: Psychotropic 
prescription utilization is prevalent among disabled Medicare beneficiaries < 65. 
Patterns of use vary by psychotropic therapeutic class. Future research needs to 
evaluate psychotropic prescription access and quality of use among this vulner-
able population.
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OBJECTIVES: The use of attention-deficit/hyperactivity disorder (ADHD) medi-
cations has been increasing among children, adolescents and adults but little 
is known about its usage pattern, and treatment adherence among distinct age 
groups in Canada. This study sought to characterize utilization patterns of ADHD 
drugs approved for use in Canada with a special focus on the non-stimulant drug, 
atomoxetine. METHODS: Prescription data and anonymized longitudinal patient 
level data from IMS Brogan were used. Descriptive statistics were used to charac-
terize drug utilization patterns from 2010-2014. Utilization trends were analyzed 
with respect to age, gender, concomitant medications and physician specialty 
of the prescribing physician. Adherence patterns for atomoxetine were meas-
ured by the medication possession ratio (MPR). RESULTS: IMS data indicate that 
the average annual prescription volume of all ADHD drugs in Canada have been 
increasing each year (35% increase from 2,795,226 in 2009 to 3,772,266 in 2013). 
Methylphenidate stimulants accounted for approximately 70% of all prescriptions, 
and children 6-12 years accounted for most of these prescriptions. Prescriptions 
of atomoxetine showed the same increasing trends; however females aged 19-65 
accounted for most of this increase. ADHD drug use declined during the summer 
months and in 2013, over 20% of children aged 13-18 years had at least one gap of 
more than 30 days between the end of one prescription of atomoxetine and the 
start of the next. In addition, 25-35% of this age group had an MPR of less than 
80%. CONCLUSIONS: ADHD drug utilization has been increasing over the last 5 
years in Canada. Children aged 6-12 years account for most of the prescriptions, 
and they are most likely to go on a “drug holiday”. Given that serious adverse 
reactions can be associated with ADHD drugs in some children, their clinical 
benefits should be continuously and closely monitored, and weighed against their 
potential risks.
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OBJECTIVES: MAOIs were first discovered in the 1950s and used to manage depres-
sion when few alternatives existed. MAOIs block tyramine catabolism, meaning 
patients consuming tyramine rich foods (e.g. cheeses, cured meats) risk increased 
release of noradrenaline, potentially leading to hypertensive crisis. While MAOIs still 
have some role in depression management, little is known about current clinical 
practice. This study aims to audit the usage of MAOIs from 2004-2013. METHODS: 
The THIN database was used to identify all patients prescribed irreversible MAOIs 
between 01/01/2004–31/12/2013. Dates of first MAOI prescription and first depression 
diagnosis were identified, along with age, social deprivation score and repeat MAOI 
prescriptions. RESULTS: 886 patients were prescribed MAOIs during 2004-2013, 44% 
of which were new prescriptions. Median age at first use was 53years (IQR 43-63), M:F 
ratio was 1:1.8 and 49% were in the 2 most affluent quintiles. The median time from 
first depression diagnosis to first MAOI prescription was 11.2years (IQR 4.3-21.1). 
From 2004-2013, MAOI usage decreased from 555 to 248 patients, with treatment 
initiation falling from 72 to 28 patients. Median age of treated patients increased 
from 63 to 68years and 4-8% had concurrent SSRI prescriptions. Median prescrip-
tion use was 8.8months (IQR 5.1-11.0) in each year, with per patient prescriptions 
ranging from 37 (IQR 20-69) to 54 (IQR 27-83). Median time on MAOI from 2004-2013 
was 1.7years (IQR 0.4-4.8). CONCLUSIONS: THIN is a representative sample of 6% 
of the UK population. This study projects an estimated 600 UK patients start MAOIs 
yearly, with numbers decreasing. Estimated UK MAOI usage has fallen from 9,000 to 
4,000 patients during 2004-2013. Records indicate that patients are receiving shorter, 
more frequent prescriptions. NICE guidelines confirm that MAOIs still have some 
role in depression management, although not defined. This is the first large study 
to audit changes in MAOI usage.
cal therapies (e.g., motivational interviewing). The effectiveness of BH screening 
in PC settings is related to the availability of adequate treatment and follow-up 
systems of care. CONCLUSIONS: Increasing evidence is available concerning the 
effectiveness of BH-PH integration/collaboration strategies in treating depressive 
and anxiety symptoms and medical/clinical outcomes. Improved stratification of 
BH-PH integration models will determine the relative success of different integra-
tion approaches. Additional studies are needed in adolescents and people with 
schizophrenia and bipolar disorder.
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OBJECTIVES: The illicit production of methamphetamine from the precursor 
chemical pseudoephedrine (PSE) in clandestine laboratories poses a public health 
risk for our communities and a financial burden on law enforcement. Previous 
work has shown a strong relationship between PSE sales and clandestine labs 
in Kentucky. The purpose of this project is to extend the study to Illinois and 
Louisiana and refine the model by adding additional explanatory variables and 
control variables. METHODS: Regression models predicting clandestine metham-
phetamine lab incidents using 2011 to 2012 county-level data for Kentucky, Illinois 
and Louisiana were calculated. Explanatory factors include PSE sales (in grams), 
population density, percent of adults with a high school diploma and percent pop-
ulation unemployed. Data sources include the National Precursor Log Exchange 
(NPLEx), the National Clandestine Laboratory Seizure report data received from 
the Drug Enforcement Agency, Federal Bureau of Investigation Crime in the United 
States statistics and the Census Bureau American Community Survey. RESULTS: 
Results indicate a strong positive relationship between PSE sales and clandestine 
labs (p< 0.01). Counties with a more highly educated population (p< 0.05) on aver-
age have fewer lab while a more rural population on average is associated with 
greater number of labs (p< 0.05). Individually, sales of PSE are strongly correlated 
to labs in both Kentucky and Illinois, but not Louisiana. CONCLUSIONS: PSE sales 
have a strong relationship to clandestine labs. Counties with greater sales of PSE 
have a greater number of clandestine labs, controlling for counties with no labs 
reported. These findings are an important addition to our previous work provid-
ing evidence for a strong association between PSE sales and clandestine labs in 
multiple states over multiple years and have important policy implications as 
states struggle with policy options to reduce methamphetamine production in 
their communities.
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OBJECTIVES: To assess treatment patterns, patient characteristics, and out-
comes for respondents with depression who were prescribed benzodiazepines 
(BZDs). METHODS: Survey-eligible adults with ≥ 2 medical claims for depression 
from 6/1/2009-5/31/2010 in the HealthCore Integrated Research Database were 
invited to participate in this retrospective/prospective study. Consenting respond-
ents completed index and 6-month post-index surveys assessing depression, anxi-
ety, and other health measures. Respondents’ survey data were linked to 24 months 
of claims data. Respondents with and without BZD prescriptions ±6 months from 
index survey date were identified. Healthcare utilization and costs were assessed 
pre- and post-index survey date and compared across users and non-users using 
descriptive statistics. RESULTS: Of 970 respondents who completed both surveys, 
638 (66%) were prescribed BZDs and 332 (34%) were not. Respondents with and with-
out BZD prescriptions were similar. Mean age was 47.9 and 45.7 years, respectively. 
The majority of respondents were female, overweight/obese, married/cohabiting, 
and college educated. Respondents prescribed BZDs were more likely to have pre-
index diagnoses of double depression (10.8% vs. 6.6%, p= .0338), anxiety (90.4% vs. 
65.7%, p< .0001), and a higher mean Quan-Charlson Comorbidity Index score (0.7 
vs. 0.5, p= .0393) as well as higher depression, fatigue, pain, insomnia, and anxiety 
index survey scores. Tricyclic antidepressants, serotonin–norepinephrine reuptake 
inhibitors, and second-generation antipsychotic use were higher for respondents 
prescribed BZDs (all p< .05). Mental health-related resource utilization involving 
psychiatrist visits was significantly higher for respondents prescribed BZDs at base-
line and follow-up (all p< .05). Although total annual medical mental health–related 
costs were similar ($3, 492 vs. $3,054, p= .5229), pharmacy and psychiatrist visit 
costs were significantly greater for respondents prescribed BZDs CONCLUSIONS: 
A majority of respondents with depression also had anxiety and were prescribed 
BZDs. Results suggest that BZD use was associated with more pronounced comor-
bid conditions and symptoms of depression, as well as higher health care resource 
utilization and costs.
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OBJECTIVES: One-third of Medicare beneficiaries < 65, who are deemed eligible for 
Social Security Disability Insurance, are disabled due to a mental disorder. But psy-
chiatric services research targeting this population is limited. This study estimated 
annual trends in and identified factors associated with psychotropic prescription 
utilization among disabled Medicare beneficiaries < 65. METHODS: This serial cross-
sectional study used 2002-2009 Medicare Current Beneficiary Survey data. Nationally 
